Method of treating heart failure
Disclosed herein is a method for treating heart failure in a subject in need thereof. The method includes administering a therapeutically effective amount of nicotinamide riboside to the subject. The heart failure may be associated with iron deficiency. The method may also include administering iron to the subject.
1. A method for treating heart failure in a subject in need thereof, the method comprising administering a therapeutically effective amount of nicotinamide riboside to the subject, wherein the subject has mitochondrial dysfunction, and wherein nicotinamide riboside is administered to the subject in an amount of from about 500 mg/day to about 2000 mg/day.
2. The method of claim 1 , wherein the subject has iron deficiency.
3. The method of claim 1 , wherein the subject has a decreased NAD/NADH ratio as compared to a NAD/NADH ratio of a subject not suffering from heart failure.
4. The method of claim 1 , further comprising administering iron to the subject.
5. The method of claim 1 , wherein a lifespan of the subject is extended as compared to a lifespan of a subject suffering from heart failure and not administered nicotinamide riboside.
6. A method for treating heart failure in a subject in need thereof, the method comprising administering a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of iron to the subject, wherein the subject has mitochondrial dysfunction, and wherein nicotinamide riboside is administered to the subject in an amount of from about 500 mg/day to about 2000 mg/day.
7. The method of claim 6 , wherein the heart failure is associated with iron deficiency.
8. A method for treating heart failure associated with iron deficiency in a subject in need thereof, the method comprising administering a therapeutically effective amount of nicotinamide riboside to the subject, wherein the subject has mitochondrial dysfunction, and wherein nicotinamide riboside is administered to the subject in an amount of from about 500 mg/day to about 2000 mg/day.
9. The method of claim 8 , wherein the iron deficiency is in the heart of the subject.
10. The method of claim 8 , wherein the subject has a decreased NAD/NADH ratio as compared to a NAD/NADH ratio of a subject not suffering from heart failure associated with iron deficiency.
11. The method of claim 8 , further comprising administering iron to the subject.
12. The method of claim 8 , wherein a lifespan of the subject is extended as compared to a lifespan of a subject suffering from heart failure associated with iron deficiency and not administered nicotinamide riboside.
13. A method for treating heart failure associated with iron deficiency in a subject in need thereof, the method comprising administering a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of iron to the subject, wherein the subject has mitochondrial dysfunction, and wherein nicotinamide riboside is administered to the subject in an amount of from about 500 mg/day to about 2000 mg/day.